ACAD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACADIA Pharmaceuticals looks like a good buy right now for a beginner investor with a long-term horizon and $50,000-$100,000 to deploy. My view is a clear BUY. The stock just had a strong daily move to 22.57, technicals are improving, the latest quarter showed revenue growth, and management reaffirmed full-year guidance. Wall Street sentiment is broadly constructive with multiple Buy/Outperform ratings and raised targets, and there is no negative insider or congress trading pressure. Because the user is impatient and does not want to wait for a perfect entry, the current setup is acceptable for initiating a position now rather than waiting.
ACAD is in a short-term upward trend. Price closed at 22.57, above the pivot of 22.214 and near resistance at 22.867, with MACD histogram positive and expanding, which supports bullish momentum. RSI_6 at 57.8 is neutral-to-bullish and does not show an overbought condition. Moving averages are converging, suggesting a possible trend continuation if momentum holds. The stock also gained 5.03% in regular trading, which confirms near-term strength.
In Q1 2026, ACAD reported revenue of $268.1M, up 9.72% YoY, which is a healthy top-line growth trend for the latest quarter season. DAYBUE sales were strong at $101M, up 20% YoY, supporting the growth story. However, profitability weakened materially: net income fell 80.84% YoY to $3.64M and EPS dropped 81.82% YoY to $0.02. Gross margin remained high at 90.75% but slipped slightly from last year. Overall, the company is still growing, but earnings quality is uneven.
Wall Street pros are moderately bullish. Recent actions include BofA upgrading ACAD to Buy, JPMorgan raising its target to $34 with an Overweight rating, TD Cowen keeping Buy and raising target to $37, and Citizens keeping Outperform with a $35 target. RBC slightly lowered its target to $29 but kept Outperform, while some firms such as Morgan Stanley and Stifel were more cautious. Net view: more bulls than bears, with the target range clustering mostly in the high 20s to mid 30s, and the consensus tone remains positive.
